Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-11

  Law, Jennifer H ^a   Li, Yvonne ^b   To, Karen ^a   Wang, Michelle ^a   Astanehe, Arezoo ^a   Lambie, Karen ^c   Dhillon, Jaspreet ^a   Jones, Steven J M ^b   Gleave, Martin E ^c   Eaves, Connie J ^c   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DECOY CELL PERMEABLE PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL IMMORTALIZATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE AMPLIFICATION; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOSIS INHIBITION; MOLECULAR DOCKING; PROSTATE CANCER; PROTEIN BINDING; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; AMINO ACID SEQUENCE; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; Y-BOX-BINDING PROTEIN 1;

EID: 77958556510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012661     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Marrett LD, De P, Airia P, Dryer D (2008) Cancer in Canada in 2008. CMAJ 179: 1163-1170.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci, USA 98: 10869-10874.
4. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
5. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N (2009) HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Tar 9: 419-438.
6. Hadaschik BA, Sowery RD, Gleave ME (2007) Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 17: 182-187.
7. Mellado B, Codony J, Ribal MJ, Visa L, Gascon P (2009) Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 11: 5-10.
8. Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-490.
9. Wu J, Stratford AL, Astanehe A, Dunn SE (2007) YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics 2: 1-17.
10. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, et al. (2006) Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879.
11. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, et al. (2008) Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86.
12. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, et al. (2004) The trancription factor YB-1 is upregulated during prostate cancer progression and increases P-glycoprotein expression. Prostate 59: 337-349.
13. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, et al. (1998) Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4(9): 2273-2277.
14. Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K (2001) Expression of Y box-binding protein 1 correlates with DNA topoisomerase II alpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res 221(4A): 2357-2362.
15. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, et al. (2001) Nuclear expression of Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7: 3151-3155.
16. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, et al. (1999) Enhanced coexpression of YB-1 and DNA polymerase II genes in human colorectal carcinomas. Int J Cancer 83: 732-737.
17. Faury D, Nantel A, Dunn SE, Guiot M, Haque T, et al. (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma. J Clin Onc 25(10): 1196-1208.
18. Gao Y, Fotovati A, Lee C, Wang M, Cote G, et al. (2009) Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 8: 3276-3284.
19. Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, et al. (2009) Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 4: 1066-1074.
20. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, et al. (2005) Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292.
21. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, et al. (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10: R99.
22. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, et al. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65: 1027-1034.
23. Clark DE, Errington TM, Smith JA, Frierson HF, Jr., Weber MJ, et al. (2005) The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65: 3108-3116.
24. Carriere A, Ray H, Blenis J, Roux PP (2008) The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13: 4258-4275.
25. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450.
26. Kabouridis PS (2003) Biological applications of protein transduction technology. Trends Biotechnol 21: 498-503.
27. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, et al. (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7: 457-468.
28. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, et al. (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9: 940-944.
29. Abagyan R, Totrov M, Kuznetsov D (1994) ICM - A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comput Chem 15: 488.
30. To K, Zhao Y, Jiang H, Hu K, Wang M, et al. (2007) The phosphoinositide- dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoro- methyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol 72: 641-652.
31. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, et al. (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9: R61.
32. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, et al. (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246.
33. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, et al. (2008) Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/ STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68: 8661-8666.
34. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13(16): 4909-4919.
35. Stingl J, Raouf A, Emerman JT, Eaves CJ (2005) Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol 10: 49-59.
36. Raouf A, Zhao Y, To K, Stingl J, Delaney A, et al. (2008) Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3: 109-118.
37. Stingl J, Eaves CJ, Kuusk U, Emerman JT (1998) Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation 63: 201-213.
38. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ (1996) Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood 88: 3765-3773.
39. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, et al. (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450.
40. Chatterjee M, Rancso C, Stuhmer T, Eckstein N, Andrulis M, et al. (2008) The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111: 3714-3722.
41. Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482.
42. Orange JS, May MJ (2008) Cell penetrating peptide inhibitors of nuclear factor- kappa B. Cell Mol Life Sci 65: 3564-3591.
43. Bidwell GL, 3rd, Davis AN, Raucher D (2009) Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 135: 2-10.
44. Yoshikawa T, Sugita T, Mukai Y, Abe Y, Nakagawa S, et al. (2009) The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains. Biomaterials 30: 3318-3323.
45. Prive GG, Melnick A (2006) Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Genet Dev 16: 71-77.
46. Verdine GL, Walensky LD (2007) The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264-7270.